Avalon GloboCare Corp. (AVCO): Price and Financial Metrics
AVCO Price/Volume Stats
|Current price||$0.53||52-week high||$1.08|
|Prev. close||$0.63||52-week low||$0.38|
|Day high||$0.65||Avg. volume||142,644|
|50-day MA||$0.52||Dividend yield||N/A|
|200-day MA||$0.60||Market Cap||52.18M|
AVCO Stock Price Chart Interactive Chart >
Avalon GloboCare Corp. (AVCO) Company Bio
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology. In addition, the company develops proprietary diagnostic and therapeutic products leveraging exosome technology; and provides development services for hospitals. The company has a strategic partnership with Weill Cornell Medical College to co-develop bio-production and standardization procedures for chimeric antigen receptor (CAR)-T Therapy; GensKey Medical Technology Co. Ltd. to co-develop and commercialize point-of-care, rapid detection antibody tests to identify whether a patient has been exposed to and has developed antibodies against SARS-CoV-2; GE Healthcare to enhance standardized automation and bio-production for cellular medicines; and HydroPeptide, LLC to co-develop and commercialize various clinical-grade, exosome-based cosmeceutical and orthopedic products, as well as research agreement with Massachusetts Institute of Technology to develop CAR technology. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.
AVCO Latest News Stream
|Loading, please wait...|
AVCO Latest Social Stream
View Full AVCO Social Stream
Latest AVCO News From Around the Web
Below are the latest news stories about AVALON GLOBOCARE CORP that investors may wish to consider to help them evaluate AVCO as an investment opportunity.
Company to Begin Trading under New Symbol “ALBT” on November 10, 2022 Symbol Change Better Reflects Avalon’s New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced that its ticker symbol will change on the NASDAQ Stock Exchange from “AVCO” to “ALBT” at the open of market trading on Thu
Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million
Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a private placement of $15 million of Avalon preferred stock, convertible at a floor of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up Company to Begin Trading under New Symbol “ALBT” on November
Avalon GloboCare Corp (NASDAQ: AVCO) has agreed to acquire a 60% interest in Laboratory Services MSO LLC, a premier reference laboratory. What Happened: Total consideration for the acquisition will be $31 million, including $15 million in cash, $15 million in series B preferred shares, and $1 million payable after one year of the closing of the transaction The company paid a $5 million refundable cash advance with the signing of the definitive agreement. Additionally, Laboratory Services will ha
Investors in Avalon GloboCare (NASDAQ:AVCO) from five years ago are still down 72%, even after 32% gain this past week
Avalon GloboCare Corp. ( NASDAQ:AVCO ) shareholders will doubtless be very grateful to see the share price up 32% in...
Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer of Avalon GloboCare, will be presenting at the 15th annual LD Micro Main Event being held on October 25 - 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.Presentatio
AVCO Price Returns